Use of Polymyxin-B hemoperfusion in rapidly progressive interstitial lung disease associated with anti-MDA5
DOI:
https://doi.org/10.32818/reccmi.a8n1a10Keywords:
rapidly progressive interstitial lung disease, anti-MDA5, dermatomyositis, hemoperfusion, polymyxin BAbstract
Dermatomyositis associated with anti-MDA5 antibodies encompasses different clinical phenotypes like cutaneous vasculopathy, rheumatological disease, and rapidly progressive interstitial lung disease, which imply a worse prognosis. This amount of involvement can be a challenge in clinical practice due to the complexity of finding a diagnosis and the treatment's refractoriness.
Starting a combination therapy based on high-dose glucocorticoids and classical immunosuppressants is recommended. Experts have described other treatments for refractory cases such as plasmapheresis, IV immunoglobulins, tofacitinib, or Polymyxin-B hemoperfusion.
Downloads
Metrics
References
Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology. 2020; 95(1): e70-e78. doi: https://doi.org/10.1212/WNL.0000000000009727 (ultimo acceso mar. 2023). DOI: https://doi.org/10.1212/WNL.0000000000009727
Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K et al. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Respir Med. 2018; 140: 1-5. doi: https://doi.org/10.1016/j.rmed.2018.05.010 (último acceso mar. 2023). DOI: https://doi.org/10.1016/j.rmed.2018.05.010
González-Moreno J, Raya-Cruz M, Losada-López I, Cacheda A, Oliver C, Colom B. Rapidly progressive interstitial lung disease due to anti-MDA 5 antibodies without skin involvement: a case report and literature review. Rheumatology International. 2018; 38: 1293-1296. doi: https://doi.org/10.1007/s00296-018-3991-7 (último acceso ene. 2023). DOI: https://doi.org/10.1007/s00296-018-3991-7
Selva-O'Callaghan A, Romero-Bueno F, Trallero-Araguás E, Gil-Vila A, Ruiz-Rodríguez JC, Sánchez-Pernaute O et al. Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease. Curr Treatm Opt Rheumatol. 2021; 7(4): 319-333. doi: https://doi.org/10.1007/s40674-021-00186-x (último acceso mar. 2023). DOI: https://doi.org/10.1007/s40674-021-00186-x
Fujisawa, T. Management of myositis-associated interstitial lung disease. Medicina. [Internet]. 2021; 57(4): 347. doi: https://doi.org/10.3390/medicina57040347 (último acceso feb.2023). DOI: https://doi.org/10.3390/medicina57040347
Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, Ruiz-Rodríguez JC, Castellvi I, Rodriguez-Nieto MJ, Martínez-Becerra MJ et al; MEDRA5 (Spanish MDA5 Register) group. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020; 50(4): 776-790. doi: https://doi.org/10.1016/j.semarthrit.2020.03.007 (último acceso dic. 2022). DOI: https://doi.org/10.1016/j.semarthrit.2020.03.007
Hamada-Ode K, Taniguchi Y, Kimata T, Kawaguchi Y, Shimamura Y, Kuwana M et al. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. Eur J Rheumatol. 2015; 2(2): 83-85. Accesible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047270/pdf/ejr-2-2-83.pdf (último acceso mar. 2023). DOI: https://doi.org/10.5152/eurjrheum.2015.0076
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Laura Jiménez-de la Cruz , Laura Martínez-Díaz, Ismael Calero-Paniagua
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
